JMDC Posts Double-Digit Profit Growth and Confirms Full-Year Outlook for FY2025

JMDC Inc. ( (JP:4483) ) just unveiled an announcement.

JMDC reported strong consolidated results for the nine months ended December 31, 2025, with revenue from continuing operations rising 23.2% year on year to ¥36.5 billion and operating profit climbing 37.1% to ¥7.8 billion, while profit attributable to owners of the parent increased 24.6% to ¥4.8 billion. EBITDA expanded to ¥9.7 billion, reflecting improved profitability after the divestiture of the dispensing pharmacy support business, and the balance sheet strengthened with total assets of ¥156.2 billion and equity attributable to owners at ¥81.9 billion, though the equity ratio dipped slightly to 52.4%. The company maintained a zero interim dividend for the current fiscal year and left its full-year forecast unchanged, projecting ¥50.5 billion in revenue and ¥7.4 billion in profit attributable to owners, implying continued double-digit top-line and earnings growth, which underscores management’s confidence in sustained expansion of its core healthcare data business despite only modest growth expected at the bottom line for the full year.

The most recent analyst rating on (JP:4483) stock is a Hold with a Yen3449.00 price target. To see the full list of analyst forecasts on JMDC Inc. stock, see the JP:4483 Stock Forecast page.

More about JMDC Inc.

JMDC Inc. is a Japan-based company listed on the Tokyo Stock Exchange that operates under IFRS and focuses on healthcare-related data and services, providing analytics and solutions primarily to medical institutions, insurers and corporate clients. The company has been refining its portfolio, including the reclassification and transfer of its dispensing pharmacy support business, to concentrate on higher-growth, data-driven healthcare operations.

Average Trading Volume: 314,175

Technical Sentiment Signal: Sell

Current Market Cap: Yen208.7B

See more data about 4483 stock on TipRanks’ Stock Analysis page.